Related Experiment Video
Updated: Jun 12, 2026
07:35
A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
CD4-/CD56+/CD123+ Hematodermic Neoplasm Showing Early Liver Metastasis
Kyu-Won Choi1, Ki-Yeol Lee, Yeong-Kyu Lee
1Department of Dermatology, College of Medicine, Dong-A University, Busan, Korea.
Annals of Dermatology
|June 16, 2010
Summary
This study reports a rare case of CD4-/CD56+ Hematodermic Neoplasm (HN) with early liver metastasis. Despite aggressive treatment, the patient experienced relapse and succumbed to the disease.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hematodermic Neoplasm (HN) is an aggressive malignancy with frequent skin and potential leukemic involvement.
- The WHO-EORTC classification renamed blastic natural killer cell lymphoma to CD4+/CD56+ HN, originating from plasmacytoid dendritic cell precursors.
- Diagnostic challenges arise in HN cases lacking CD4 or CD56 expression.
Observation:
- A 68-year-old Korean male presented with CD4-/CD56+ HN.
- The patient received hyper-CVAD chemotherapy followed by high-dose methotrexate/cytarabine.
- Despite initial remission, the disease relapsed, leading to fatal bone and brain involvement within 6 months.
Findings:
- This report details an unusual case of CD4-/CD56+/CD123+ HN.
- The neoplasm exhibited early liver metastasis, an uncommon presentation.
- Despite comprehensive diagnostic workups, including imaging and biopsy, the aggressive nature of the disease was evident.
Implications:
- The case underscores the diagnostic difficulties associated with atypical HN presentations.
- Further cytogenetic studies, such as comparative genomic hybridization, are crucial for understanding HN pathogenesis.
- Identifying novel therapeutic targets and diagnostic markers for rare HN subtypes is essential for improving patient outcomes.
